Publikationen

Bornhäuser M, Schliemann C, Schetelig J, Röllig C, Kramer M, Glass B, Platzbecker U, Burchert A, Hänel M, Müller LP, Klein S, Bug G, Beelen D, Rösler W, Schäfer-Eckart K, Schmid C, Jost E, Lenz G, Tischer J, Spiekermann K, Pfirrmann M, Serve H, Stölzel F, Alakel N, Middeke JM, Thiede C, Ehninger G, Berdel WE, Stelljes M. Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical Trial. JAMA ONCOL 2023, 9:519

Katzerke C, Schaffrath J, Lützkendorf J, Janssen M, Merbach AK, Nerger K, Binder M, Baum C, Lauer K, Rohde C, Willscher E, Müller-Tidow C, Mueller LP. Reduced proliferation of bone marrow MSC after allogeneic stem cell transplantation is associated with clinical outcome. BLOOD ADV 2023, 7:2811.

Kröger N, Wulf G, Hegenbart U, Burchert A, Stelljes M, Gagelmann N, Brecht A, Kaufmann M, Müller LP, Ganser A, Wolf D, Bethge W, Bornhäuser M, Kiehl M, Wagner EM, Schmid C, Reinhardt C, Kobbe G, Salwender H, Heinicke T, Kropff M, Heinzelmann M, Ayuk F, Trümper L, Neubauer A, Völp A, Kluychnikov E, Schönland S, Wolschke C. Autologous-allogeneic vs. autologous tandem stem cell transplantation and maintenance therapy with thalidomide for patients with multiple myeloma (MM) and age <60 years: A prospective phase II-study. HAEMATOLOGICA 2023     

Heise N, Lehmann F, Csuk R and Mueller T: Targeted theranostics: Near-infrared triterpenoic acid-rhodamine conjugates as prerequisites for precise cancer diagnosis and therapy. Eur J Med Chem 2023, 259: 115663.

Kraft O, Hartmann AK, Brandt S, Hoenke S, Heise NV, Csuk R and Mueller T: Asiatic acid as a leading structure for derivatives combining sub-nanomolar cytotoxicity, high selectivity, and the ability to overcome drug resistance in human preclinical tumor models. Eur J Med Chem 2023, 250: 115189.

Rotermund A, Staege MS, Brandt S, Luetzkendorf J, Lucas H, Mueller LP and Mueller T: Luciferase Expressing Preclinical Model Systems Representing the Different Molecular Subtypes of Colorectal Cancer. Cancers (Basel) 2023, 15, (16): 4122.

Rotermund A, Brandt S, Staege MS, Luetzkendorf J, Mueller LP and Mueller T: Differential CMS-Related Expression of Cell Surface Carbonic Anhydrases IX and XII in Colorectal Cancer Models-Implications for Therapy. Int J Mol Sci 2023, 24, (6): 5797.

Schleser SW, Krytovych O, Ziegelmeier T, Gross E, Kasparkova J, Brabec V, Weber T, Schobert R and Mueller T: Palladium and Platinum Complexes of the Antimetabolite Fludarabine with Vastly Enhanced Selectivity for Tumour over Non-Malignant Cells. Molecules 2023, 28, (13): 5173.

Roska J, Lobo J, Ivovic D, Wachsmannova L, Mueller T, Henrique R, Jeronimo C, Chovanec M and Jurkovicova D: Integrated Microarray-Based Data Analysis of miRNA Expression Profiles: Identification of Novel Biomarkers of Cisplatin-Resistance in Testicular Germ Cell Tumours. Int J Mol Sci 2023, 24, (3): 2495.

Heise N, Becker S, Mueller T, Bache M, Csuk R and Guttler A: Mitochondria-Targeting 1,5-Diazacyclooctane-Spacered Triterpene Rhodamine Conjugates Exhibit Cytotoxicity at Sub-Nanomolar Concentration against Breast Cancer Cells. Int J Mol Sci 2023, 24, (13): 10695.

Gross E, Hilger RA, Schumann FL, Bauer M, Bouska A, Rohde C, Willscher E, Lutzkendorf J, Muller LP, Edemir B, Mueller T, Herling M, Binder M, Wickenhauser C, Iqbal J, Posern G and Weber T: SAM-Competitive EZH2-Inhibitors Induce Platinum Resistance by EZH2-Independent Induction of ABC-Transporters. Cancers (Basel) 2023, 15, (11): 3043.

Engelmann R, Jaekel N, Jotschke S, Ludwig-Kraus B, Kraus FB, Kumari N, Schulze S, Hecker M, Zahn C, Al-Ali HK, Junghanss C, Böttcher S.Vector-based SARS-CoV-2 vaccination is associated with improved T-cell responses in hematological neoplasia., Blood Adv. 2023 Mar 22:bloodadvances.2022009054. doi: 10.1182/bloodadvances. 2022009054.

Raphael Itzykson, MD, PhD^1,2,3; Valeria Santini, MD^4,5; Sylvain Thepot, MD^3,6; Lionel Ades, MD, PhD^1,3,7; Cendrine Chaffaut, MSc⁸; Aristoteles Giagounidis, MD^9,10; Margot Morabito, BSc¹¹; Nathalie Droin, PhD¹¹; Michael Lübbert, MD^10,12; Rosa Sapena, PhD³; Stanislas Nimubona, MD^3,13; Jean Goasguen, MD¹⁴; Eric Wattel, MD, PhD^3,15; Gina Zini, MD, PhD^16,17; Jose Miguel Torregrosa Diaz, MD^3,18; Ulrich Germing, MD^10,19; Anna Maria Pelizzari, MD^5,20; Sophie Park, MD, PhD^3,21; Nadja Jaekel, MD^10,22; Georgia Metzgeroth, MD^10,23; Francesco Onida, MD^5,24; Robert Navarro, MD^3,25; Andrea Patriarca, MD^5,26; Aspasia Stamatoullas, MD^3,27; Katharina Götze, MD^10,28; Martin Puttrich, MSc^10,29; Sandra Mossuto, MSc⁵; Eric Solary, MD^3,11,30; Silke Gloaguen, MSc^10,31; Sylvie Chevret, MD, PhD⁸; Fatiha Chermat, DMD³; Uwe Platzbecker, MD^10,31; and Pierre Fenaux, MD, PhD, Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network, DOI: 10.1200/JCO.22.00437 Journal of Clinical Oncology 41, no. 10 (April 01, 2023) 1888-1897.

Verstovsek S, Gerds AT, Vannucchi AM, Al-Ali HK, Lavie D, Kuykendall AT, Grosicki S, Iurlo A, Goh YT, Lazaroiu MC, Egyed M, Fox ML, McLornan D, Perkins A, Yoon SS, Gupta V, Kiladjian JJ, Granacher N, Lee SE, Ocroteala L, Passamonti F, Harrison CN, Klencke BJ, Ro S, Donahue R, Kawashima J, Mesa R; MOMENTUM Study Investigators. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study. Lancet. 2023 Jan 28;401(10373):269-280. doi: 10.1016/S0140-6736(22)02036-0.

Vannucchi AM, Al-Ali HK, Lavie D, Kuykendall AT, Grosicki S, Iurlo A, Goh YT, Lazaroiu MC, Egyed M, Fox ML, McLornan D, Perkins A, Yoon SS, Gupta V, Kiladjian JJ, Granacher N, Lee SE, Ocroteala L, Passamonti F, Harrison CN, Oh S, Klencke BJ, Yu J, Donahue R, Kawashima J, Mesa R. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study. Lancet Haematol. 2023 Sep;10(9):e735-e746. doi: 10.1016/S2352-3026(23)00174-6. Epub 2023 Jul 27. PMID: 37517413.

Isfort S, Manz K, Teichmann LL, Crysandt M, Burchert A, Hochhaus A, Saussele S, Kiani A, Göthert JR, Illmer T, Schafhausen P, Al-Ali HK, Stegelmann F, Hänel M, Pfeiffer T, Giagounidis A, Franke GN, Koschmieder S, Fabarius A, Ernst T, Warnken-Uhlich M, Wolber U, Kohn D, Pfirrmann M, Wolf D, Brümmendorf TH; German CML study group. Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study. Ann Hematol. 2023 Oct;102(10):2741-2752. doi: 10.1007/s00277-023-05394-0. Epub 2023 Aug 18. PMID: 37592092; PMCID: PMC10492675.

Rummelt C, Grishina O, Schmoor C, Crysandt M, Heuser M, Götze KS, Schlenk RF, Döhner K, Salih HR, Heil G, Müller-Tidow C, Brugger W, Kündgen A, De Wit M, Giagounidis A, Scholl S, Neubauer A, Krauter J, Bug G, Al-Ali HK, Wäsch R, Becker H, May AM, Duyster J, Hackanson B, Ganser A, Döhner H, Lübbert M. Activity of decitabine combined with all-trans retinoic acid in oligoblastic acute myeloid leukemia: results from a randomized 2x2 phase II trial (DECIDER). Haematologica. 2023 Aug 1;108(8):2244-2248. doi: 10.3324/haematol.2022.282258. PMID: 36601981; PMCID: PMC10388266.

Palandri F, Al-Ali HK, Guglielmelli P, Zuurman MW, Sarkar R, Gupta V. Benefit of Early Ruxolitinib Initiation Regardless of Fibrosis Grade in Patients with Primary Myelofibrosis: A Post Hoc Analysis of the Single-Arm Phase 3b JUMP Study. Cancers (Basel). 2023 May 22;15(10):2859. doi: 10.3390/cancers15102859. PMID: 37345196; PMCID: PMC10216208

Felser S, Rogahn J, Hollenbach L, Gruen J, le Coutre P, Al-Ali HK, Schulze S, Muegge LO, Kraze-Kliebhahn V, Junghanss C. Physical exercise recommendations for patients with polycythemia vera based on preferences identified in a large international patient survey study of the East German Study Group for Hematology and Oncology (OSHO #97). Cancer Med. 2023 Sep;12(17):18235-18245. doi: 10.1002/cam4.6413. Epub 2023 Aug 9. PMID: 37559463; PMCID: PMC10523957.

Niederwieser D, Lang T, Krahl R, Heinicke T, Maschmeyer G, Al-Ali HK, Schwind S, Jentzsch M, Cross M, Kahl C, Wolf HH, Sayer H, Schulze A, Dreger P, Hegenbart U, Krämer A, Junghanss C, Mügge LO, Hähling D, Hirt C, Späth C, Peter N, Opitz B, Florschütz A, Reifenrath K, Zojer N, Scholl S, Pönisch W, Heyn S, Vucinic V, Hochhaus A, Aul C, Giagounidis A, Balleisen L, Oldenkott B, Staib P, Kiehl M, Schütte W, Naumann R, Eimermacher H, Dörken B, Sauerland C, Lengfelder E, Hiddemann W, Wörmann B, Müller-Tidow C, Serve H, Schliemann C, Hehlmann R, Berdel WE, Pfirrmann M, Krug U, Hoffmann VS. Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study. Ann Hematol. 2023 Mar;102(3):547-561. doi: 10.1007/s00277-023-05087-8. Epub 2023 Jan 25. PMID: 36695874; PMCID: PMC9977880.

Lückmann SL, Böhme G, Krüger F, Hiemer S, Al-Ali HK, Wuppermann A. Finanzielle Beeinflussung medizinischer Entscheidungen in Deutschland – Eine Übersichtsarbeit zu Ursachen und Forschungsstand von ökonomischen Einflüssen in der stationären Versorgung [Financial Influence on Medical Decisions in Germany - A Review of the Reasons and State of Research on Economization in Inpatient Care]. Dtsch Med Wochenschr. 2023 Jul;148(14):916-920. German. doi: 10.1055/a-2091-4029. Epub 2023 Jul 7. PMID: 37493953.

Reipsch F, Biersack B, Lucas H, Schobert R and Mueller T: Imidazole Analogs of Vascular-Disrupting Combretastatin A-4 with Pleiotropic Efficacy against Resistant Colorectal Cancer Models. Int J Mol Sci 2021, 22, (23): 13082

Lacouture ME, Sibaud V, Gerber PA, van den Hurk C, Fernández-Peñas P, Santini D, Jahn F, Jordan K; ESMO Guidelines Committee. Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines☆. Ann Oncol. 2021 Feb;32(2):157-170. doi: 10.1016/j.annonc.2020.11.005. Epub 2020 Nov 25. PMID: 33248228.

Schultheiß C, Paschold L, Willscher E, Simnica D, Wöstemeier A, Muscate F, Wass M, Eisenmann S, Dutzmann J, Keyßer G, Gagliani N, Binder M. Maturation trajectories and transcriptional landscape of plasmablasts and autoreactive B cells in COVID-19. iScience.

Simnica D*, Schultheiß C*, Mohme M*, Paschold L, Willscher E, Fitzek A, Püschel K, Matschke J, Ciesek S, Sedding DG, Zhao Y, Gagliani N, Maringer Y, Walz JS, Heide J, Schulze-zur-Wiesch J, Binder M. Landscape of T cell repertoires with public COVID-19-associated T cell receptors in pre-pandemic risk cohorts. Clin Transl Immunology August 28. doi.org/10.1002/cti2.1340.

Grehl C*, Schultheiß C*, Hoffmann K, Binder M, Altmann T, Grosse I, Kuhlmann M. Detection of SARS-CoV-2 derived small RNAs and changes in circulating small RNAs associated with COVID-19. Viruses 13(8), 1593; doi.org/10.3390/v13081593.

Porritt RA*, Binek A*, Paschold L*, Noval Rivas M, Mc Ardle A, Yonker LM, Alter G, Chandnani HK, Lopez M, Fasano A, Van Eyk JE**, Binder M**, Arditi M*. The autoimmune signature of hyperinflammatory multisystem inflammatory syndrome in children. J Clin Invest. 2021 Aug 26:151520. doi: 10.1172/JCI151520.

Stein A*, Simnica D*, Schultheiß C*, Scholz R, Tintelnot J, Goekkurt E, von Wenserski L, Willscher E, Paschold L, Sauer M, Lorenzen S, Riera-Knorrenschild J, Depenbusch R, Ettrich T, Doerfel S, Al-Batran SE, Karthaus, M, Pelzer U, Waberer L, Hinke A, Bauer M, Massa C, Seliger B, Wickenhauser C, Bokemeyer C, Hegewisch-Becker S, Binder M. PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer. J Immunother Cancer Jul;9(7):e002844. doi: 10.1136/jitc-2021-002844.

Thiele B, Binder M, Schliffke S, Frenzel C, Dierlamm J, Wass M, Weisel KC, Bokemeyer C, Janjetovic S. Outcome of a Real-World Patient Cohort with Secondary CNS Lymphoma Treated with High-Intensity Chemoimmunotherapy and Autologous Stem Cell Transplantation. Oncol Res Treat. 2021;44(7-8):375-381. doi: 10.1159/000517531.

Bußmann L, Hoffer K, von Bargen CM, Droste C, Lange T, Kemmling J, Schröder-Schwarz J, Vu AT, Akingunsade L, Nollau P, Rangarajan S, de Wijn R, Oetting A, Müller C, Böckelmann LC, Zech HB, Berger JC, Möckelmann N, Busch CJ, Böttcher A, Gatzemeier F, Klinghammer K, Simnica D, Binder M, Struve N, Rieckmann T, Schumacher U, Clauditz TS, Betz CS, Petersen C, Rothkamm K, Münscher A, Kriegs M. Analyzing tyrosine kinase activity in head and neck cancer by functional kinomics: Identification of hyperactivated Src family kinases as prognostic markers and potential targets. Int J Cancer. 2021 Sep 1;149(5):1166-1180. doi: 10.1002/ijc.33606.

Paschold L, Willscher E, Bein J, Vornanen M, Eichenauer DA, Simnica D, Thiele B, Wickenhauser C, Rosenwald A, Bernd HW, Klapper W, Feller AC, Ott G, Fend F, Hartmann S, Binder M. Evolutionary clonal trajectories in nodular lymphocyte-predominant Hodgkin lymphoma with high risk of transformation. Haematologica. 2021 Oct 1;106(10):2654-2666. doi: 10.3324/haematol.2021.278427.

Chernyakov D, Groß A, Fischer A, Bornkessel N, Schultheiss C, Gerloff D, Edemir B. Loss of RANBP3L leads to transformation of renal epithelial cells towards a renal clear cell carcinoma like phenotype. J Exp Clin Cancer Res 40, 226. doi.org/10.1186/s13046-021-01982-y.

Porritt RA*, Paschold L*, Rivas MN, Cheng MH, Yonker LM, Chandnani H, Lopez M, Simnica S, Schultheiß C, Santiskulvong C, Van Eyk J, McCormick JK, Fasano A, Bahar I, Binder M**, Arditi M**. HLA Class I-associated expansion of TRBV11-2 T cells in Multisystem Inflammatory Syndrome in Children. J Clin Invest. May 17;131(10):e146614. doi: 10.1172/JCI146614.

Zhao Y, Kilian C, Turner JE, Bosurgi L, Roedl K, Bartsch P, Gnirck AC, Cortesi F, SchultheißC, Hellmig M, Enk LUB, Hausmann F, Borchers A, Wong MN, Paust HJ, Siracusa F, Scheibel N, Herrmann M, Rosati E, Bacher P, Kylies D, Jarczak D, Lütgehetmann M, Pfefferle S, Steurer S, Schulze-zur-Wiesch J, Puelles V, Sperhake JP, Addo M, Lohse AW, Binder M, Huber S,  Huber TB, Kluge S, Bonn S, Panzer U, Gagliani N, Krebs CF. Clonal expansion and activation of tissue-resident memory-like Th17 cells expressing GM-CSF in the lung of severe COVID-19 patients. Sci Immunol 2021. Feb 23;6(56):eabf6692. doi: 10.1126/sciimmunol.abf6692.

Paschold L*, Simnica D*, Willscher E, Vehreschild MJGT, Dutzmann J, Sedding DG, Schultheiß C, Binder  M. SARS-CoV-2 specific antibody rearrangements in pre-pandemic immune repertoires of risk cohorts and COVID-19 patients. J Clin Invest. 2021 Jan 4;131(1):e142966. doi: 10.1172/JCI142966.

von Wenserski L, Schultheiß C, Bolz S, Schliffke S, Simnica D, Willscher E, Gerull H, Bobusch A-L, Riecken K, Fehse B, Altfeld M, Nollau P, Binder M. SLAMF receptors negatively regulate B cell rece­ptor signaling in chronic lymphocytic leukemia via prohibitin-2. Leukemia. 2021. Apr;35(4):1073-1086. doi.org/10.1038/s41375-020-01025-z.

Schultheiß C, Simnica D, Willscher E, Oberle A, Fanchi LF, Bonzanni N, Wildner N, Schulze-Zur-Wiesch J, Weiler-Normann C, Lohse AW, Binder M. Next-generation immunosequencing reveals pathological T cell architecture in autoimmune hepatitis. Hepatology. 2021 Apr;73(4):1436-1448. doi: 10.1002/hep.31473.

Wass M, Göllner S, Besenbeck B, Schlenk RF, Mundmann P, Göthert JR, Noppeney R, Schliemann C, Mikesch JH, Lenz G, Dugas M, Wermke M, Röllig C, Bornhäuser M, Serve H, Platzbecker U, Foerster KI, Burhenne J, Haefeli WE, Müller LP, Binder M, Pabst C, Müller-Tidow C; Study Alliance Leukemia (SAL). A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy. Leukemia. 2021 Mar;35(3):701-711. doi: 10.1038/s41375-020-0892-z.

Bauer M, Vaxevanis C, Al-Ali HK, Jaekel N, Naumann CLH, Schaffrath J, Rau A, Seliger B, Wickenhauser C. Altered Spatial Composition of the Immune Cell Repertoire in Association to CD34+ Blasts in Myelodysplastic Syndromes and Secondary Acute Myeloid Leukemia. Cancers (Basel). 2021 Jan 7;13(2):186. doi: 10.3390/cancers13020186. PMID: 33430322; PMCID: PMC7825771.

Schuler E, Wagner-Drouet EM, Ajib S, Bug G, Crysandt M, Dressler S, Hausmann A, Heidenreich D, Hirschbühl K, Hoepting M, Jost E, Kaivers J, Klein S, Koldehoff M, Kordelas L, Kriege O, Müller LP, Rautenberg C, Schaffrath J, Schmid C, Wolff D, Haas R, Bornhäuser M, Schroeder T, Kobbe G; German Cooperative Transplant Study Group. Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group. Ann Hematol. 2021 Apr;100(4):959-968. doi: 10.1007/s00277-020-04321-x. Epub 2020 Nov 16. Erratum in: Ann Hematol. 2021 Aug;100(8):2141-2142. PMID: 33191481; PMCID: PMC8448702.

Nalbadis, A.; Trutschel, M.-L.; Lucas, H.; Luetzkendorf, J.; Meister, A.; Mäder, K. Selection and Incorporation of siRNA Carrying Non-Viral Vector for Sustained Delivery from Gellan Gum Hydrogels. Pharmaceutics2021, 13, 1546

Rose R, Kemper B, Schwab A, Schlatter E, Edemir B (2021). Unexpected localization of AQP3 and AQP4 induced by migration of primary cultured IMCD cells. Sci Rep. Jun 7;11(1):11930.

Cui C, Liu Y, Gerloff D, Rohde C, Pauli C, Köhn M, Misiak D, Oellerich T, Schwartz S, Schmidt LH, Wiewrodt R, Marra A, Hillejan L, Bartel F, Wickenhauser C, Hüttelmaier S, Göllner S, Zhou F, Edemir B, Müller-Tidow C(2021). NOP10 predicts lung cancer prognosis and its associated small nucleolar RNAs drive proliferation and migration. Oncogene. Feb;40(5):909-921.

Schümann, F, Bauer M, Groß, E, Terziev, D, Wienke A, Wickenhauser C, Binder, M, Weber, T. RBMX protein expression in T-cell lymphomas predicts chemotherapy response and prognosis. Cancers, 2021;13:4788.

Weber T, Schmidberger A, Ligeti K, Bauer M, Rosenwald A, Müller LP. Presence of Parvovirus B19 but not Herpesvirus genome in acute skin rash after allogeneic stem cell transplantation correlates with outcome. Acta Haematologica. 2021;144(2):202-211

Liebers N, Duell J, Fitzgerald D, Kerkhoff A, Noerenberg D, Kaebisch E, Acker F, Fuhrmann S, Leng C, Welslau M, Chemnitz J, Middeke JM, Weber T, Holtick U, Trappe R, Pfannes R, Liersch R, Spoer C, Fuxius S, Gebauer N, Caillé L, Geer T, Koenecke C, Keller U, Claus R, Mougiakakos D, Mayer S, Huettmann A, Pott C, Trummer A, Wulf G, Brunnberg U, Bullinger L, Hess G, Mueller-Tidow C, Glass B, Lenz G, Dreger P, Dietrich S. Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas. Blood Adv. 2021;5(13):2707-2716

Schümann F, Weber T. Periphere T-Zell-Lymphome – Neue zielgerichtete Therapien auf dem Vormarsch in die Klinik. Onkologie heute. 2021;(6):34-39

Cervantes F, Ross D, Radinoff A, Palandri F, Myasnikov A,Vannucchi A, Zachee P, Gisslinger A,  Komatsu N, Foltz L, Mannelli N, Passamonti F,  Gilotti G, Sadek I,  Tiwari R, Zor E, Al-Ali HK. Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the RREALISE phase 2 study. Leukemia 2021.

Schulze S , Jaekel N , Naumann C , Haak A , Bauer M , Wickenhauser C, Al-Ali HK. Clinical Discernment, Bone Marrow, and Molecular Diagnostics Are Equally Important to Solve the Phenotypic Mimicry among Subtypes of Myeloproliferative Neoplasms. Reports 2021, 4, 27.

Gupta V, Griesshammer M, Martino B, Foltz L, Tavares R, Al-Ali HK, Giraldo P, Guglielmelli P, Lomaia E, Bouard C, Paley C, Tiwari R, Zor E, Raanani P. Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study, Leuk and Lymphoma 2021: 62(4):918-926.

Thomas Heinicke, MD1, Rainer Krahl, PhD2, Christoph Kahl, MD3, Michael Cross, PhD2, Sebastian Scholl, MD4, Hans-Heinrich Wolf, MD5, Detlev Hähling, MD6, Ute Hegenbart, MD7, Norma Peter, MD8, Antje Schulze, MD9, Axel Florschütz, MD10, Schmidt Volker9; Kolja Reifenrath11, Niklas Zojer, MD12, Christian Junghanss, MD13, Herbert G. Sayer, MD9, Georg Maschmeyer, MD14, Späth Christian15, MD, Andreas Hochhaus, MD4, Thomas Fischer, MD1, Haifa Kathrin Al-Ali, MD5* and Dietger Niederwieser, MD. Allogeneic hematopoietic stem cell transplantation improves long term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials. Annals of Hematology. Annals of Hematology (2021) 100:2387–2398

Gecht U, Tsoukakis I, Kricheldorf K , Stegelmann F , Klausmann M , Griesshammer M , Schulz H , Hollburg W , Göthert J , Sockel K , Heidel F , Gattermann N, Maintz C, Al-Ali HK, Platzbecker U , Hansen R, Hänel M, Parmentier S, Bommer M, Pahl H, Lang F , Kirschner M, Isfort S, Brümmendorf T, Döhner K, Koschmieder S.  Kidney Dysfunction Is Associated with Thrombosis and Disease Severity in Myeloproliferative Neoplasms: Implications from the German Study Group for MPN Bioregistry. Cancers 2021.

Passemonti F, Gupta V, Martino B, Foltz L L, Zaritskey A,  Al-Ali HK, Tavares R, Maffioli M, Raanani P, Giraldo P,  Griesshammer M, Guglielmelli P, Bouard C,  Paley C, Tiwari R, Vannucchi A. Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low, intermediate-1-, intermediate-2-, and high-risk myelofibrosis in JUMP, a phase IIIb, expanded-access study. Hematological Oncology 2021

Roska J, Wachsmannova L, Hurbanova L, Sestakova Z, Mueller T, Jurkovicova D and Chovanec M: Differential gene expression in cisplatin-resistant and -sensitive testicular germ cell tumor cell lines. Oncotarget 2020, 11, (51): 4735-4753.

Birndt S, Schenk T, Heinevetter B, Brunkhorst FM, Maschmeyer G, Rothmann F, Weber T, Müller M, Panse J, Penack O, Schroers R, Braess J, Frickhofen N, Ehl S, Janka G, Lehmberg K, Pletz MW, Hochhaus A, Ernst T, La Rosée P, Hemophagocytic lymphohistiocytosis in adults: collaborative analysis of 137 cases of a nationwide German registry. Cancer Res Clin Oncol. 2020 Apr;146(4):1065-1077. doi: 10.1007/s00432-020-03139-4. Epub 2020 Feb 20.J Cancer Res Clin Oncol. 2020. PMID: 32076823

Cheng MH, Zhang S, Porritt RA, Rivas MN, Paschold L, Willscher E, Binder M, Arditi M, Bahar I. An insertion unique to SARS-CoV-2 spike exhibits superantigenic character strengthened by recent mutations. PNAS

Ciarimboli G., Theil G., Bialek J., Edemir B.: (2020) Contribution and Expression of Organic Cation Transporters and Aquaporin Water Channels in Renal Cancer. Reviews of Physiology Biochemistry and Pharmacology, 48: 1-10 32772272

Edemir B.: (2020) Identification of Prognostic Organic Cation and Anion Transporters in Different Cancer Entities by In Silico Analysis. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 21: 1-10 32599841

Fagnan A., Bagger F.O., Piqué-Borràs M.R., Ignacimouttou C., Caulier A., Lopez C., Robert E., Uzan B., Gelsi-Boyer V., Aid Z., Thirant C., Moll U., Tauchmann S., Kurtovic-Kozaric A., Maciejewski J.P., Dierks C., Spinelli O., Salmoiraghi S., Pabst T., Shimoda K., Deleuze V., Lapillonne H., Sweeney C., Mansat-De Mas V., Leite B., Kadri Z., Malinge S., de Botton S., Micol J.B., Kile B.T., Carmichael C.L., Iacobucci I., Mullighan C.G., Carroll M.P., Valent P., Bernard O.A., Delabesse E., Vyas P., Birnbaum D., Anguita E., Garcon L., Soler E., Schwaller J., Mercher T.: (2020) Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers. BLOOD, Epub: Epub 32350520

Gerloff D., Lützkendorf J., Moritz R.K.C., Wersig T., Mäder K., Müller L.P., Sunderkötter C.: (2020) Melanoma-Derived Exosomal miR-125b-5p Educates Tumor Associated Macrophages (TAMs) by Targeting Lysosomal Acid Lipase A (LIPA). Cancers, 12: 1-23 32079286

Groß A., Chernyakov D., Gallwitz L., Bornkessel N., Edemir B.: (2020) Deletion of Von Hippel-Lindau Interferes with Hyper Osmolality Induced Gene Expression and Induces an Unfavorable Gene Expression Pattern. Cancers, 12: 2-12 32059438

Kaiser M., Edemir B.: (2020) Lithium Chloride and GSK3 Inhibition Reduce Aquaporin-2 Expression in Primary Cultured Inner Medullary Collecting Duct Cells Due to Independent Mechanisms. Cells, 9: 1-10 32340354

Kreutmair S., Erlacher M., Andrieux G., Istvanffy R., Mueller-Rudorf A., Zwick M., Rückert T., Pantic M., Poggio T., Shoumariyeh K., Mueller T.A., Kawaguchi H., Follo M., Klingeberg C., Wlodarski M., Baumann I., Pfeifer D., Kulinski M., Rudelius M., Lemeer S., Kuster B., Dierks C., Peschel C., Cabezas-Wallscheid N., Duque-Afonso J., Zeiser R., Cleary M.L., Schindler D., Schmitt-Graeff A., Boerries M., Niemeyer C.M., Oostendorp R.A., Duyster J., Illert A.L.: (2020) Loss of the Fanconi anemia-associated protein NIPA causes bone marrow failure. JOURNAL OF CLINICAL INVESTIGATION, 130: 2827-2844 32338640

Metz S, Tintelnot J, Trentmann M, Oberle A, von Wenserski L, Schultheiß C, Braig F, Fehse B, Riecken K, Bokemeyer C, Stein A, Binder M. Cancer cells expressing oncogenic Rat sarcoma show drug-addiction towards epidermal growth factor receptor antibodies mediated by sustained mitogen-activated protein kinase signaling, Front Oncol. 2020 Jan 21;9:1559. doi: 10.3389/fonc.2019.01559. eCollection 2019

Mezger N.C.S., Feuchtner J., Griesel M., Hämmerl L., Seraphin T.P., Zietsman A., Péko J.F., Tadesse F., Buziba N.G., Wabinga H., Nyanchama M., Borok M.Z., Kéita M., N'da G., Lorenzoni C.F., Akele-Akpo M.T., Gottschick C., Binder M., Mezger J., Jemal A., Parkin D.M., Wickenhauser C., Kantelhardt E.J.: (2020) Clinical presentation and diagnosis of adult patients with non-Hodgkin lymphoma in Sub-Saharan Africa. BRITISH JOURNAL OF HAEMATOLOGY, 190: 209-221 32181503

Michallet M., Dreger P., Sobh M., Koster L., Hoek J., Boumendil A., Scheid C., Fox C.P., Wulf G., Krüger W., van Gelder M., Corradini P., Russo D., Passweg J., Schoemans H., Bethge W., Schaap N., Cornelissen J., Browne P., Durakovic N., Muller L., Montoto S., Kroger N., Schetelig J., French Cooperative Group for CLL SFGM-TC and the EBMT Chronic Malignancy and Lymphoma Working Parties: (2020) Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia. BONE MARROW TRANSPLANTATION, 55: 884-890 31700137

Mohme M., Maire C.L., Geumann U., Schliffke S., Dührsen L., Fita K., Akyüz N., Binder M., Westphal M., Guenther C., Lamszus K., Hermann F.G., Schmidt N.O.: (2020) Local Intracerebral Immunomodulation Using Interleukin-Expressing Mesenchymal Stem Cells in Glioblastoma. CLINICAL CANCER RESEARCH, 26: 2626-2639 31988196

Noack AK, Lucas H, Chytil P, Etrych T, Mader K, and Mueller T: Intratumoral Distribution and pH-Dependent Drug Release of High Molecular Weight HPMA Copolymer Drug Conjugates Strongly Depend on Specific Tumor Substructure and Microenvironment. Int J Mol Sci2020;21: 6029.

Pauli C., Liu Y., Rohde C., Cui C., Fijalkowska D., Gerloff D., Walter C., Krijgsveld J., Dugas M., Edemir B., Pabst C., Mueller L.P., Zhou F., Müller-Tidow C.: (2020) Site-specific methylation of 18S ribosomal RNA by SNORD42A is required for acute myeloid leukemia cell proliferation. BLOOD, 135: 2059-2070 32097467

Pouyiourou M, Meyer A, Stroux A, Viardot A,La Rosée P, Maschmeyer G, Kämpfe D, Kahl C, Vucinic V, Monecke A, Hirt C, Weber T, Meissner J, Witzens-Harig M, Böttcher S, Schmalenberg H, Marks R, Prange-Krex G, Kroschinsky F, Hauf E, Keller U, Koch K, Klapper W, Herold M, Scholz CW; First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A-results of a retrospective analysis. East German Study Group for Hematology and Oncology (OSHO). Ann Hematol. 2020 Jul 30. doi: 10.1007/s00277-020-04171-7. Online ahead of print.Ann Hematol. 2020. PMID: 32734548

Schriewer L., Schütze K., Petry K., Hambach J., Fumey W., Koenigsdorf J., Baum N., Menzel S., Rissiek B., Riecken K., Fehse B., Röckendorf J.L., Schmid J., Albrecht B., Pinnschmidt H., Ayuk F., Kröger N., Binder M., Schuch G., Hansen T., Haag F., Adam G., Koch-Nolte F., Bannas P.: (2020) Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies. THERANOSTICS, 10: 2645-2658 32194826

Schultheiß C., Paschold L., Simnica D., Mohme M., Willscher E., von Wenserski L., Scholz R., Wieters I., Dahlke C., Tolosa E., Sedding D.G., Ciesek S., Addo M., Binder M.: (2020) Next-Generation Sequencing of T and B Cell Receptor Repertoires from COVID-19 Patients Showed Signatures Associated with Severity of Disease. IMMUNITY, 53: 442-455.e4 32668194

Schultheiß C., Simnica D., Willscher E., Oberle A., Fanchi L., Bonzanni N., Wildner N.H., Schulze-Zur-Wiesch J., Weiler-Normann C., Lohse A.W., Binder M.: (2020) Next-generation immunosequencing reveals pathological T cell architecture in autoimmune hepatitis. HEPATOLOGY, 3: 1-10 32692457

Simnica D, Ittrich H, Bockemeyer C, Stein A, Binder M. Targeting the mutational landscape of bystander cells: Drug-promoted blood cancer from high-prevalence pre-neoplasias in patients on BRAF inhibitors, Frontiers in Oncology,

Szenes E., Härzschel A., Decker S., Tissino E., Pischeli J., Gutjahr J.C., Kissel S., Pennisi S., Höpner J.P., Egle A., Zaborsky N., Dierks C., Follo M., Chigaev A., Zucchetto A., Greil R., Gattei V., Hartmann T.N.: (2020) TCL1 transgenic mice as a model for CD49d-high chronic lymphocytic leukemia. LEUKEMIA, Epub: Epub 32086446

Terziev D., Bauer M., Paschold L., Wickenhauser C., Wienke A., Binder M., Müller L.P., Weber T.: (2020) Impact of bone marrow involvement on outcome in relapsed and refractory transplant eligible diffuse large B-cell lymphoma and transformed indolent lymphoma. PLoS One, 15: e0235786 32639975

Tintelnot J., Goekkurt E., Binder M., Thuss-Patience P., Lorenzen S., Knorrenschild J.R., Kretzschmar A., Ettrich T., Lindig U., Jacobasch L., Pink D., Al-Batran S.E., Hinke A., Hegewisch-Becker S., Nilsson S., Bokemeyer C., Stein A.: (2020) Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217). BMC CANCER, 20: 503 32487035

von Wenserski L., Schultheiß C., Bolz S., Schliffke S., Simnica D., Willscher E., Gerull H., Wolters-Eisfeld G., Riecken K., Fehse B., Altfeld M., Nollau P., Binder M.: (2020) SLAMF receptors negatively regulate B cell receptor signaling in chronic lymphocytic leukemia via recruitment of prohibitin-2. LEUKEMIA, 6: 1-10 32826957

von Wenserski L, Schultheiß C, Bolz S, Schliffke S, Simnica D, Willscher E, Gerull H, Bobusch A-L, Riecken K, Fehse B, Altfeld M, Nollau P, Binder M. SLAMF receptors negatively regulate B cell receptor signaling in chronic lymphocytic leukemia via recruitment of prohibitin-2, Leukemia

Wass M., Göllner S., Besenbeck B., Schlenk R.F., Mundmann P., Göthert J.R., Noppeney R., Schliemann C., Mikesch J.H., Lenz G., Dugas M., Wermke M., Röllig C., Bornhäuser M., Serve H., Platzbecker U., Foerster K.I., Burhenne J., Haefeli W.E., Müller L.P., Binder M., Pabst C., Müller-Tidow C., Study Alliance Leukemia (SAL): (2020) A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy. LEUKEMIA, Epub: Epub 32561840

Weber T, Schmidberger A, Ligeti K, Bauer M, Rosenwald A, Müller LP. Presence of Parvovirus B19 but not Herpesvirus genome in acute skin rash after allogeneic stem cell transplantation correlates with outcome. ACTA HAEMATOLOGICA 2020

Zech HB, Moeckelmann N, Boettcher A, Muenscher A, Binder M, Vettorazzi E, Bokemeyer C, Schafhausen P, Betz CS, Busch C-J. Phase III study of nivolumab alone or combined with ipilimumab as immunotherapy versus standard of care in resectable head and neck squamous cell carcinoma, Future Oncology

Simnica D, Smits M, Willscher E, Fanchi LF, Kloots ISH, van Oort I, Gerritsen W, Mehra N, Binder M. Responsiveness to Immune Checkpoint Inhibitors Is Associated With a Peripheral Blood T-Cell Signature in Metastatic Castration-Resistant Prostate Cancer. JCO Precis Oncol. l4:1374-138. DOI: 10.1200/PO.20.00209

Brandt A., Matschke J., Fehrle W., von Wenserski L., Bokemeyer C., Illerhaus G., Binder M.: (2019) A significant proportion of patients with primary central nervous system lymphoma harbor clonal bone marrow B-cells. LEUKEMIA & LYMPHOMA, 60: 334-340 30033830

Decker S., Zwick A., Khaja Saleem S., Kissel S., Rettig A., Aumann K., Dierks C.: (2019) Optimized Xenograft Protocol for Chronic Lymphocytic Leukemia Results in High Engraftment Efficiency for All CLL Subgroups. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 20: 6277 31842407

Dreger P., Michallet M., Bosman P., Dietrich S., Sobh M., Boumendil A., Nagler A., Scheid C., Cornelissen J., Niederwieser D., Müller L., Vandenberghe E., Scortechini I., Schoemans H., Andersen N.S., Finke J., Russo D., Ljungman P., Passweg J., van Gelder M., Durakovic N., Labussiere-Wallet H., Berg T., Wulf G., Bethge W., Bunjes D., Stilgenbauer S., Canepari M.E., Schaap M., Fox C.P., Kröger N., Montoto S., Schetelig J.: (2019) Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties. BONE MARROW TRANSPLANTATION, 54: 44-52 29728701

Gomes de Castro M.A., Wildhagen H., Sograte-Idrissi S., Hitzing C., Binder M., Trepel M., Engels N., Opazo F.: (2019) Differential organization of tonic and chronic B cell antigen receptors in the plasma membrane. Nature Communications, 10: 820 30778055

Harrach S., Barz V., Pap T., Pavenstädt H., Schlatter E., Edemir B., Distler J., Ciarimboli G., Bertrand J.: (2019) Notch Signaling Activity Determines Uptake and Biological Effect of Imatinib in Systemic Sclerosis Dermal Fibroblasts. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 139: 439-447 30273596

Janjetovic S., Asemissen A.M., Dicker F., Binder M., Dierlamm J., Bokemeyer C., Schafhausen P.: (2019) Fulminant blast crisis with de novo 11q23 rearrangement in a Philadelphia-positive CML patient undergoing treatment with dasatinib. Tumori J, 105: NP8-NP11 30935343

Jordan B, Zierz S, Weber T, Jordan K.Jordan B, et al. Muscle Nerve. 2019 Jul;60(1):Successful use of an immune checkpoint inhibitor in a patient with myasthenia gravis in remission. E7-E8. doi: 10.1002/mus.26495. Epub 2019 May 7.Muscle Nerve. 2019. PMID: 31018243

Kandabarau S., Leiz J., Krohn K., Winter S., Bedke J., Schwab M., Schaeffeler E., Edemir B.: (2019) Hypertonicity-Affected Genes Are Differentially Expressed in Clear Cell Renal Cell Carcinoma and Correlate with Cancer-Specific Survival. Cancers, 12: E6 31861377

Mährle T., Akyüz N., Fuchs P., Bonzanni N., Simnica D., Germing U., Asemissen A.M., Jann J.C., Nolte F., Hofmann W.K., Nowak D., Binder M.: (2019) Deep sequencing of bone marrow microenvironments of patients with del(5q) myelodysplastic syndrome reveals imprints of antigenic selection as well as generation of novel T-cell clusters as a response pattern to lenalidomide. HAEMATOLOGICA, 104: 1355-1364 30655375

Mueller T., Freystein J., Lucas H., Schmoll H.J.: (2019) Efficacy of a Bispecific Antibody Co-Targeting VEGFA and Ang-2 in Combination with Chemotherapy in a Chemoresistant Colorectal Carcinoma Xenograft Model. MOLECULES, 24: 2865 31394786

Müller T.A., Pennisi S., Zwick A., Decker S., Klein C., Rister B., Rudorf A., Kissel S., Follo M., Wäsch R., Illert A.L., Pfeifer D., Oostendorp R., Waskow C., Dierks C., Duyster J.: (2019) PIM1 inhibition effectively enhances plerixafor-induced HSC mobilization by counteracting CXCR4 upregulation and blocking CXCL12 secretion. LEUKEMIA, 33: 1296-1301 30816332

Rossi A., Voigtlaender M., Klose H., Schlüter H., Schön G., Loges S., Paolini M., Bokemeyer C., Reck M., Tarro G., Binder M.: (2019) High Aldehyde Dehydrogenase Levels Are Detectable in the Serum of Patients with Lung Cancer and May Be Exploited as Screening Biomarkers. Journal of Oncology, 2019: 8970645 31534455

Schieferdecker A., Binder M., Weisel K., Bokemeyer C.: (2019) [Monoclonal Gammopathy Of Unknown Significance - A Common Incidental Finding - What is to be thought of? What has to be done?]. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 144: 982-989 31311049

Schliffke S., Carambia A., Akyüz N., Thiele B., Herkel J., Binder M.: (2019) T-cell repertoire profiling by nextgeneration sequencing reveals tissue migration dynamics of TRBV13-family clonotypes in a common experimental autoimmune encephalomyelitis mouse model. JOURNAL OF NEUROIMMUNOLOGY, 332: 49-56 30933850

Schmitt F., Gold M., Rothemund M., Andronache I., Biersack B., Schobert R., Mueller T.: (2019) New naphthopyran analogues of LY290181 as potential tumor vascular-disrupting agents. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 163: 160-168 30503940

Schmitt F., Gosch L.C., Dittmer A., Rothemund M., Mueller T., Schobert R., Biersack B., Volkamer A., Höpfner M.: (2019) Oxazole-Bridged Combretastatin A-4 Derivatives with Tethered Hydroxamic Acids: Structure⁻Activity Relations of New Inhibitors of HDAC and/or Tubulin Function. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 20: 383 30658435

Schulze S., Stengel R., Jaekel N., Wang S.Y., Franke G.N., Roskos M., Schneider M., Niederwieser D., Al-Ali H.K.: (2019) Concomitant and noncanonical JAK2 and MPL mutations in JAK2V617F- and MPLW515 L-positive myelofibrosis. GENES CHROMOSOMES & CANCER, 58: 747-755 31135094

Schütte-Nütgen K., Edeling M., Mendl G., Krahn M.P., Edemir B., Weide T., Kremerskothen J., Michgehl U., Pavenstädt H.: (2019) Getting a Notch closer to renal dysfunction: activated Notch suppresses expression of the adaptor protein Disabled-2 in tubular epithelial cells. FASEB JOURNAL, 33: 821-832 30052485

Simnica D., Akyüz N., Schliffke S., Mohme M., V Wenserski L., Mährle T., Fanchi L.F., Lamszus K., Binder M.: (2019) T cell receptor next-generation sequencing reveals cancer-associated repertoire metrics and reconstitution after chemotherapy in patients with hematological and solid tumors. ONCOIMMUNOLOGY, 8: e1644110 31646093

Simnica D., Schliffke S., Schultheiß C., Bonzanni N., Fanchi L.F., Akyüz N., Gösch B., Casar C., Thiele B., Schlüter J., Lohse A.W., Binder M.: (2019) High-Throughput Immunogenetics Reveals a Lack of Physiological T Cell Clusters in Patients With Autoimmune Cytopenias. Frontiers in Immunology, 10: 1897 31497012

Steinemann G., Dittmer A., Schmidt J., Josuttis D., Fähling M., Biersack B., Beindorff N., Jolante Koziolek E., Schobert R., Brenner W., Müller T., Nitzsche B., Höpfner M.: (2019) Antitumor and antiangiogenic activity of the novel chimeric inhibitor animacroxam in testicular germ cell cancer. Molecular Oncology, 13: 2679-2696 31583820

Tintelnot J., Baum N., Schultheiß C., Braig F., Trentmann M., Finter J., Fumey W., Bannas P., Fehse B., Riecken K., Schuetze K., Bokemeyer C., Rösner T., Valerius T., Peipp M., Koch-Nolte F., Binder M.: (2019) Nanobody Targeting of Epidermal Growth Factor Receptor (EGFR) Ectodomain Variants Overcomes Resistance to Therapeutic EGFR Antibodies. MOLECULAR CANCER THERAPEUTICS, 18: 823-833 30824613

Tintelnot J., Metz S., Trentmann M., Oberle A., von Wenserski L., Schultheiß C., Braig F., Kriegs M., Fehse B., Riecken K., Bokemeyer C., Stein A., Binder M.: (2019) Cancer Cells Expressing Oncogenic Rat Sarcoma Show Drug-Addiction Toward Epidermal Growth Factor Receptor Antibodies Mediated by Sustained MAPK Signaling. Frontiers in Oncology, 9: 1559 32039027

Tran C.L.H., Jaekel N., Bauer M., Emmer A., Wickenhauser C., Al-Ali H.K.: (2019) Aggressive systemic mastocytosis: a diagnostic challenge in a patient with myotonic dystrophy type 2: a case report. ANNALS OF HEMATOLOGY, 98: 2825-2827 31705184

von Felden J., Alric L., Pischke S., Aitken C., Schlabe S., Spengler U., Giordani M.T., Schnitzler P., Bettinger D., Thimme R., Xhaard A., Binder M., Ayuk F., Lohse A.W., Cornelissen J.J., de Man R.A., Mallet V.: (2019) The burden of hepatitis E among patients with haematological malignancies: A retrospective European cohort study. JOURNAL OF HEPATOLOGY, 71: 465-472 31108159

Werner S., Lützkendorf J., Müller T., Müller L.P., Posern G.: (2019) MRTF-A controls myofibroblastic differentiation of human multipotent stromal cells and their tumour-supporting function in xenograft models. Scientific Reports, 9: 11725 31409840

Wolf G., Weber T.: (2019) Periphere T‑Zell-Lymphome: Primär- und Rezidivtherapie. ONKOLOGE, 10: Online IF: 0,137;

Zeiser R., Beelen D.W., Bethge W., Bornhäuser M., Bug G., Burchert A., Christopeit M., Duyster J., Finke J., Gerbitz A., Klusmann J.H., Kobbe G., Lübbert M., Müller-Tidow C., Platzbecker U., Rösler W., Sauer M., Schmid C., Schroeder T., Stelljes M., Kröger N., Müller L.P.: (2019) Biology-Driven Approaches to Prevent and Treat Relapse of Myeloid Neoplasia after Allogeneic Hematopoietic Stem Cell Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 25: e128-e140 30658222

Ziemens A., Sonntag S.R., Wulfmeyer V.C., Edemir B., Bleich M., Himmerkus N.: (2019) Claudin 19 Is Regulated by Extracellular Osmolality in Rat Kidney Inner Medullary Collecting Duct Cells. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 20: 1-10 31500238

Comment/ Letter

Jordan B., Zierz S., Weber T., Jordan K.: (2019) Successful use of an immune checkpoint inhibitor in a patient with myasthenia gravis in remission. MUSCLE & NERVE, 60: E7-E8 31018243

Bera T.K., Abe Y., Ise T., Oberle A., Gallardo D., Liu X.F., Nagata S., Binder M., Pastan I.: (2018) Recombinant immunotoxins targeting B-cell maturation antigen are cytotoxic to myeloma cell lines and myeloma cells from patients. LEUKEMIA, 32: 569-572 29149102

Betten R., Scharner B., Probst S., Edemir B., Wolff N.A., Langelueddecke C., Lee W.K., Thévenod F.: (2018) Tonicity inversely modulates lipocalin-2 (Lcn2/24p3/NGAL) receptor (SLC22A17) and Lcn2 expression via Wnt/β-catenin signaling in renal inner medullary collecting duct cells: implications for cell fate and bacterial infection. Cell Communication and Signaling, 16: 74 30404645

Caers J., Garderet L., Kortüm K.M., O'Dwyer M.E., van de Donk N.W.C.J., Binder M., Dold S.M., Gay F., Corre J., Beguin Y., Ludwig H., Larocca A., Driessen C., Dimopoulos M.A., Boccadoro M., Gramatzki M., Zweegman S., Einsele H., Cavo M., Goldschmidt H., Sonneveld P., Delforge M., Auner H.W., Terpos E., Engelhardt M.: (2018) European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when. HAEMATOLOGICA, 103: 1772-1784 30171031

Döhner H., Dolnik A., Tang L., Seymour J.F., Minden M.D., Stone R.M., Del Castillo T.B., Al-Ali H.K., Santini V., Vyas P., Beach C.L., MacBeth K.J., Skikne B.S., Songer S., Tu N., Bullinger L., Dombret H.: (2018) Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care. LEUKEMIA, 32: 2546-2557 30275526

Heidel F.H., Al-Ali H.K., Hirt C., Kämpfe D., Jentsch-Ullrich K., Junghanss C., Nowak R., Schwarzer A., Spohn C., Vucinic V., Hochhaus A., Lange T., Working Party Myeloproliferative Neoplasms of the East German Study Group Hematology/Oncology (OSHO): (2018) Questions arising on phlebotomy in polycythemia vera: prophylactic measures to reduce thromboembolic events require patient-focused decisions. LEUKEMIA, 32: 2085-2087 30042412

Jordan K., Blättermann L., Hinke A., Müller-Tidow C., Jahn F.: (2018) Is the addition of a neurokinin-1 receptor antagonist beneficial in moderately emetogenic chemotherapy?-a systematic review and meta-analysis. SUPPORTIVE CARE IN CANCER, 26: 21-32 28861627

Kurze C., Le Conte Y., Kryger P., Lewkowski O., Müller T., Moritz R.F.A.: (2018) Infection dynamics of Nosema ceranae in honey bee midgut and host cell apoptosis. JOURNAL OF INVERTEBRATE PATHOLOGY, 154: 1-4 29550404

Mathew N.R., Baumgartner F., Braun L., O'Sullivan D., Thomas S., Waterhouse M., Müller T.A., Hanke K., Taromi S., Apostolova P., Illert A.L., Melchinger W., Duquesne S., Schmitt-Graeff A., Osswald L., Yan K.L., Weber A., Tugues S., Spath S., Pfeifer D., Follo M., Claus R., Lübbert M., Rummelt C., Bertz H., Wäsch R., Haag J., Schmidts A., Schultheiss M., Bettinger D., Thimme R., Ullrich E., Tanriver Y., Vuong G.L., Arnold R., Hemmati P., Wolf D., Ditschkowski M., Jilg C., Wilhelm K., Leiber C., Gerull S., Halter J., Lengerke C., Pabst T., Schroeder T., Kobbe G., Rösler W., Doostkam S., Meckel S., Stabla K., Metzelder S.K., Halbach S., Brummer T., Hu Z., Dengjel J., Hackanson B., Schmid C., Holtick U., Scheid C., Spyridonidis A., Stölzel F., Ordemann R., Müller L.P., Sicre-de-Fontbrune F., Ihorst G., Kuball J., Ehlert J.E., Feger D., Wagner E.M., Cahn J.Y., Schnell J., Kuchenbauer F., Bunjes D., Chakraverty R., Richardson S., Gill S., Kröger N., Ayuk F., Vago L., Ciceri F., Müller A.M., Kondo T., Teshima T., Klaeger S., Kuster B., Kim D.D.H., Weisdorf D., van der Velden W., Dörfel D., Bethge W., Hilgendorf I., Hochhaus A., Andrieux G., Börries M., Busch H., Magenau J., Reddy P., Labopin M., Antin J.H., Henden A.S., Hill G.R., Kennedy G.A., Bar M., Sarma A., McLornan D., Mufti G., Oran B., Rezvani K., Shah O., Negrin R.S., Nagler A., Prinz M., Burchert A., Neubauer A., Beelen D., Mackensen A., von Bubnoff N., Herr W., Becher B., Socié G., Caligiuri M.A., Ruggiero E., Bonini C., Häcker G., Duyster J., Finke J., Pearce E., Blazar B.R., Zeiser R.: (2018) Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITDmutant leukemia cells. NATURE MEDICINE, 24: 282-291 29431743

Mohme M., Schliffke S., Maire C.L., Rünger A., Glau L., Mende K.C., Matschke J., Gehbauer C., Akyüz N., Zapf S., Holz M., Schaper M., Martens T., Schmidt N.O., Peine S., Westphal M., Binder M., Tolosa E., Lamszus K.: (2018) Immunophenotyping of Newly Diagnosed and Recurrent Glioblastoma Defines Distinct Immune Exhaustion Profiles in Peripheral and Tumor-infiltrating Lymphocytes. CLINICAL CANCER RESEARCH, 24: 4187-4200 29444930

Mueller T., Hantsch C., Volkmer I., Staege M.S.: (2018) Differentiation-Dependent Regulation of Human Endogenous Retrovirus K Sequences and Neighboring Genes in Germ Cell Tumor Cells. Frontiers in Microbiology, 9: 1253 29963023

Prestipino A., Emhardt A.J., Aumann K., O'Sullivan D., Gorantla S.P., Duquesne S., Melchinger W., Braun L., Vuckovic S., Boerries M., Busch H., Halbach S., Pennisi S., Poggio T., Apostolova P., Veratti P., Hettich M., Niedermann G., Bartholomä M., Shoumariyeh K., Jutzi J.S., Wehrle J., Dierks C., Becker H., Schmitt-Graeff A., Follo M., Pfeifer D., Rohr J., Fuchs S., Ehl S., Hartl F.A., Minguet S., Miething C., Heidel F.H., Kröger N., Triviai I., Brummer T., Finke J., Illert A.L., Ruggiero E., Bonini C., Duyster J., Pahl H.L., Lane S.W., Hill G.R., Blazar B.R., von Bubnoff N., Pearce E.L., Zeiser R.: (2018) Oncogenic JAK2 V617F causes PD-L1 expression, mediating
immune escape in myeloproliferative neoplasms. Science Translational Medicine, 10: eaam7729 29467301

Rudat S., Pfaus A., Cheng Y.Y., Holtmann J., Ellegast J.M., Bühler C., Marcantonio D.D., Martinez E., Göllner S., Wickenhauser C., Müller-Tidow C., Lutz C., Bullinger L., Milsom M.D., Sykes S.M., Fröhling S., Scholl C.: (2018) RET-mediated autophagy suppression as targetable co-dependence in acute myeloid leukemia. LEUKEMIA, 32: 2189-2202 29654265

Ruhnke M., Behre G., Buchheidt D., Christopeit M., Hamprecht A., Heinz W., Heussel C.P., Horger M., Kurzai O., Karthaus M., Löffler J., Maschmeyer G., Penack O., Rieger C., Rickerts V., Ritter J., Schmidt-Hieber M., Schuelper N., Schwartz S., Ullmann A., Vehreschild J.J., von Lilienfeld-Toal M., Weber T., Wolf H.H.: (2018) Diagnosis of invasive fungal diseases in haematology and oncology: 2018 update of the recommendations of the infectious diseases working party of the German society for hematology and medical oncology (AGIHO). MYCOSES, 61: 796-813 30098069

Schliffke S., Buhs S., Bolz S., Gerull H., von Wenserski L., Riecken K., Fehse B., Nollau P., Binder M.: (2018) The phosphotyrosine phosphatase SHP2 promotes anergy in chronic lymphocytic leukemia. BLOOD, 131: 1755-1758 29475960

Schliffke S., Sivina M., Kim E., von Wenserski L., Thiele B., Akyüz N., Falker-Gieske C., Statovci D., Oberle A., Thenhausen T., Krohn-Grimberghe A., Bokemeyer C., Jain N., Estrov Z., Ferrajoli A., Wierda W., Keating M., Burger J.A., Binder M.: (2018) Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy. ONCOIMMUNOLOGY, 7: e1417720 29632735

Simon-Gabriel C.P., Foerster K., Saleem S., Bleckmann D., Benkisser-Petersen M., Thornton N., Umezawa K., Decker S., Burger M., Veelken H., Claus R., Dierks C., Duyster J., Zirlik K.: (2018) Microenvironmental stromal cells abrogate NF-κB inhibitor-induced apoptosis in chronic lymphocytic leukemia. HAEMATOLOGICA, 103: 136-147 29122993

Terziev D., Hutter B., Klink B., Stenzinger A., Stögbauer F., Glimm H., Fröhling S., Wickenhauser C., Jordan K., Hurtz H.J., Müller L.P., Rüssel J., Weber T.: (2018) Nivolumab maintenance after salvage autologous stem cell transplantation results in long-term remission in multiple relapsed primary CNS lymphoma. EUROPEAN JOURNAL OF HAEMATOLOGY, 101: 115-118 29624748

van Gorkom G., van Gelder M., Eikema D.J., Blok H.J., van Lint M.T., Koc Y., Ciceri F., Beelen D., Chevallier P., Selleslag D., Blaise D., Foá R., Corradini P., Castagna L., Moreno C., Solano C., Müller L.P., Tischer J., Hilgendorf I., Hallek M., Bittenbring J., Theobald M., Schetelig J., Kröger N., CLL subcommittee, Chronic Malignancies Working Party of the EBMT: (2018) Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT. BONE MARROW TRANSPLANTATION, 53: 255-263 29255169

Wass M., Bauer M., Pfannes R., Lorenz K., Odparlik A., Müller L.P., Wickenhauser C.: (2018) Chronic active Epstein-Barr virus infection of T-cell type, systemic form in an African migrant: case report and review of the literature on diagnostics standards and therapeutic options. BMC CANCER, 18: 941 30285657

Weiss V.M., Lucas H., Mueller T., Chytil P., Etrych T., Naolou T., Kressler J., Mäder K.: (2018) Intended and Unintended Targeting of Polymeric Nanocarriers: The Case of Modified Poly(glycerol adipate) Nanoparticles. MACROMOLECULAR BIOSCIENCE, 18: 1 29218838
 

Comment/ Letter

Edemir B.: (2018) Considering hypertonicity in the interpretation and analysis of cell type-specific gene expression pattern in the collecting duct. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 115: E349-E350 29311340

Weber T., Ljungman P.: (2018) Stringent vaccination of cancer patients: is it that important? ANNALS OF ONCOLOGY, 29: 1348-1349 29697738

Aapro M., Jordan K., Gralla R.J., Rizzi G., Rossi G., Palmas M., Alyasova A.V., Lisyanskaya A.S., Bošnjak S.M., Hesketh P.J.: (2017) Safety and efficacy of NEPA, an oral fixed combination of netupitant and palonosetron, in older patients. Journal of Geriatric Oncology, 8: 56-63 27889278

Akyüz N., Brandt A., Stein A., Schliffke S., Mährle T., Quidde J., Goekkurt E., Loges S., Haalck T., Ford C.T., Asemissen A.M., Thiele B., Radloff J., Thenhausen T., Krohn-Grimberghe A., Bokemeyer C., Binder M.: (2017) T-cell diversification reflects antigen selection in the blood of patients on immune checkpoint inhibition and may be exploited as liquid biopsy biomarker. INTERNATIONAL JOURNAL OF CANCER, 140: 2535-2544 27925177

Almeida A.M., Prebet T., Itzykson R., Ramos F., Al-Ali H., Shammo J., Pinto R., Maurillo L., Wetzel J., Musto P., Van De Loosdrecht A.A., Costa M.J., Esteves S., Burgstaller S., Stauder R., Autzinger E.M., Lang A., Krippl P., Geissler D., Falantes J.F., Pedro C., Bargay J., Deben G., Garrido A., Bonanad S., Diez-Campelo M., Thepot S., Ades L., Sperr W.R., Valent P., Fenaux P., Sekeres M.A., Greil R., Pleyer L.: (2017) Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 18: XY 28420120

Braig F., Brandt A., Goebeler M., Tony H.P., Kurze A.K., Nollau P., Bumm T., Böttcher S., Bargou R.C., Binder M.: (2017) Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking. BLOOD, 129: 100-104 27784674

Braig F., Kriegs M., Voigtlaender M., Habel B., Grob T., Biskup K., Blanchard V., Sack M., Thalhammer A., Ben Batalla I., Braren I., Laban S., Danielczyk A., Goletz S., Jakubowicz E., Märkl B., Trepel M., Knecht R., Riecken K., Fehse B., Loges S., Bokemeyer C., Binder M.: (2017) Cetuximab Resistance in Head and Neck Cancer Is Mediated by EGFR-K 521 Polymorphism. CANCER RESEARCH, 77: 1188-1199 28031227

Cusan M., Vegi N.M., Mulaw M.A., Bamezai S., Kaiser L.M., Deshpande A.J., Greif P.A., Quintanilla-Fend L., Göllner S., Müller-Tidow C., Humphries K.R., Armstrong S.A., Hiddemann W., Feuring-Buske M., Buske C.: (2017) Controlled stem cell amplification by HOXB4 depends on its unique proline-rich region near the N terminus. BLOOD, 129: 319-323 27827825

Ferreri A.J.M., Cwynarski K., Pulczynski E., Fox C.P., Schorb E., La Rosée P., Binder M., Fabbri A., Torri V., Minacapelli E., Falautano M., Ilariucci F., Ambrosetti A., Roth A., Hemmaway C., Johnson P., Linton K.M., Pukrop T., Sønderskov Gørløv J., Balzarotti M., Hess G., Keller U., Stilgenbauer S., Panse J., Tucci A., Orsucci L., Pisani F., Levis A., Krause S.W., Schmoll H.J., Hertenstein B., Rummel M., Smith J., Pfreundschuh M., Cabras G., Angrilli F., Ponzoni M., Deckert M., Politi L.S., Finke J., Reni M., Cavalli F., Zucca E., Illerhaus G., International Extranodal Lymphoma Study Group (IELSG): (2017) Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematology, 4: e510-e523 29054815

Fichtner M., Dreyling M., Binder M., Trepel M.: (2017) The role of B cell antigen receptors in mantle cell lymphoma. Journal of Hematology & Oncology, 10: 164 29041946

Fritsch K., Kasenda B., Schorb E., Hau P., Bloehdorn J., Möhle R., Löw S., Binder M., Atta J., Keller U., Wolf H.H., Krause S.W., Heß G., Naumann R., Sasse S., Hirt C., Lamprecht M., Martens U., Morgner A., Panse J., Frickhofen N., Röth A., Hader C., Deckert M., Fricker H., Ihorst G., Finke J., Illerhaus G.: (2017) High-dose methotrexatebased immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study). LEUKEMIA, 31: 846-852 27843136

Fumey W., Koenigsdorf J., Kunick V., Menzel S., Schütze K., Unger M., Schriewer L., Haag F., Adam G., Oberle A., Binder M., Fliegert R., Guse A., Zhao Y.J., Cheung Lee H., Malavasi F., Goldbaum F., van Hegelsom R., Stortelers C., Bannas P., Koch-Nolte F.: (2017) Nanobodies effectively modulate the enzymatic activity of CD38 and allow specific imaging of CD38 + tumors in mouse models in vivo. Scientific Reports, 7: 14289 29084989

Göllner S., Oellerich T., Agrawal-Singh S., Schenk T., Klein H.U., Rohde C., Pabst C., Sauer T., Lerdrup M., Tavor S., Stölzel F., Herold S., Ehninger G., Köhler G., Pan K.T., Urlaub H., Serve H., Dugas M., Spiekermann K., Vick B., Jeremias I., Berdel W.E., Hansen K., Zelent A., Wickenhauser C., Müller L.P., Thiede C., Müller-Tidow C.: (2017) Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia. NATURE MEDICINE, 23: 69-78 27941792

Harrach S., Edemir B., Schmidt-Lauber C., Pap T., Bertrand J., Ciarimboli G.: (2017) Importance of the novel organic cation transporter 1 for tyrosine kinase inhibition by saracatinib in rheumatoid arthritis synovial fibroblasts. Scientific Reports, 7: 1258 28455521

Hermann B., Lehners N., Brodhun M., Boden K., Hochhaus A., Kochanek M., Meckel K., Mayer K., Rachow T., Rieger C., Schalk E., Weber T., Schmeier-Jürchott A., Schlattmann P., Teschner D., von Lilienfeld-Toal M.: (2017) Influenza virus infections in patients with malignancies -- characteristics and outcome of the season 2014/15. A survey conducted by the Infectious Diseases Working Party (AGIHO) of the German Society of Haematology and Medical Oncology (DGHO). EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 36: 565-573 27838792

Jordan K., Chan A., Gralla R.J., Jahn F., Rapoport B., Warr D., Hesketh P.J.: (2017) 2016 Updated MASCC/ESMO consensus recommendations: Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents. SUPPORTIVE CARE IN CANCER, 25: 271-275 27501965

Jordan K., Feyer P., Höller U., Link H., Wörmann B., Jahn F.: (2017) Supportive Treatments for Patients with Cancer. Deutsches Arzteblatt International, Deutsches Arzteblatt International, 114: 481-487 28764837

Kasenda B., Ihorst G., Schroers R., Korfel A., Schmidt-Wolf I., Egerer G., von Baumgarten L., Röth A., Bloehdorn J., Möhle R., Binder M., Keller U., Lamprecht M., Pfreundschuh M., Valk E., Fricker H., Schorb E., Fritsch K., Finke J., Illerhaus G.: (2017) High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group. LEUKEMIA, 31: 2623-2629 28559537

Koehler P., Hamprecht A., Bader O., Bekeredjian-Ding I., Buchheidt D., Doelken G., Elias J., Haase G., Hahn-Ast C., Karthaus M., Kekulé A., Keller P., Kiehl M., Krause S.W., Krämer C., Neumann S., Rohde H., La Rosée P., Ruhnke M., Schafhausen P., Schalk E., Schulz K., Schwartz S., Silling G., Staib P., Ullmann A., Vergoulidou M., Weber T., Cornely O.A., Vehreschild M.J.G.T.: (2017) Epidemiology of invasive aspergillosis and azole resistance in patients with acute leukaemia: the SEPIA Study. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 49: 218-223 27989379

Körbelin J., Hunger A., Alawi M., Sieber T., Binder M., Trepel M.: (2017) Optimization of design and production strategies for novel adeno-associated viral display peptide libraries. GENE THERAPY, 24: 470-481 28622288

Kröger N., Iacobelli S., Franke G.N., Platzbecker U., Uddin R., Hübel K., Scheid C., Weber T., Robin M., Stelljes M., Afanasyev B., Heim D., Deliliers G.L., Onida F., Dreger P., Pini M., Guidi S., Volin L., Günther A., Bethge W., Poiré X., Kobbe G., van Os M., Brand R., de Witte T.: (2017) Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial). JOURNAL OF CLINICAL ONCOLOGY, 35: 2157-2164 28463633

Lützkendorf J., Wieduwild E., Nerger K., Lambrecht N., Schmoll H.J., Müller-Tidow C., Müller L.P.: (2017) Resistance for Genotoxic Damage in Mesenchymal Stromal Cells Is Increased by Hypoxia but Not Generally Dependent on p53-Regulated Cell Cycle Arrest. PLoS One, 12: e0169921 28081228

Macherey S., Monsef I., Jahn F., Jordan K., Yuen K.K., Heidenreich A., Skoetz N.: (2017) Bisphosphonates for advanced prostate cancer. Cochrane Database of Systematic Reviews, 12: CD006250 29278410

Mohr S., Doebele C., Comoglio F., Berg T., Beck J., Bohnenberger H., Alexe G., Corso J., Ströbel P., Wachter A., Beissbarth T., Schnütgen F., Cremer A., Haetscher N., Göllner S., Rouhi A., Palmqvist L., Rieger M.A., Schroeder T., Bönig H., Müller-Tidow C., Kuchenbauer F., Schütz E., Green A.R., Urlaub H., Stegmaier K., Humphries R.K., Serve H., Oellerich T.: (2017) Hoxa9 and Meis1 Cooperatively Induce Addiction to Syk Signaling by Suppressing miR-146a in Acute Myeloid Leukemia. CANCER CELL, 31: 549-562.e11 28399410

Mueller T., Pfankuchen D.B., Wantoch von Rekowski K., Schlesinger M., Reipsch F., Bendas G.: (2017) The Impact of the Low Molecular Weight Heparin Tinzaparin on the Sensitization of Cisplatin-Resistant Ovarian Cancers-Preclinical In Vivo Evaluation in Xenograft Tumor Models. MOLECULES, 22: E728 28467373

Oberle A., Brandt A., Alawi M., Langebrake C., Janjetovic S., Wolschke C., Schütze K., Bannas P., Kröger N., Koch-Nolte F.,  Bokemeyer C., Binder M.: (2017) Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection. HAEMATOLOGICA, 102: e368-e370 28522580

Oberle A., Brandt A., Voigtlaender M., Thiele B., Radloff J., Schulenkorf A., Alawi M., Akyüz N., März M., Ford C.T., Krohn-Grimberghe A., Binder M.: (2017) Monitoring multiple myeloma by next-generation sequencing of V(D)J rearrangements from circulating myeloma cells and cell-free myeloma DNA. HAEMATOLOGICA, 102: 1105-1111 28183851

Olver I., Ruhlmann C.H., Jahn F., Schwartzberg L., Rapoport B., Rittenberg C.N., Clark-Snow R.: (2017) 2016 Updated MASCC/ESMO Consensus Recommendations: Controlling nausea and vomiting with chemotherapy of low or minimal emetic potential. SUPPORTIVE CARE IN CANCER, 25: 297-301 27572335

Roila F., Warr D., Hesketh P.J., Gralla R., Herrstedt J., Jordan K., Aapro M., Ballatori E., Rapoport B.: (2017) 2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy. SUPPORTIVE CARE IN CANCER, 25: 289-294 27510316

Rossi A., Voigtlaender M., Janjetovic S., Thiele B., Alawi M., März M., Brandt A., Hansen T., Radloff J., Schön G., Hegenbart U., Schönland S., Langer C., Bokemeyer C., Binder M.: (2017) Mutational landscape reflects the biological continuum of plasma cell dyscrasias. Blood Cancer Journal, 7: e537 28234344

Ruhlmann C.H., Jahn F., Jordan K., Dennis K., Maranzano E., Molassiotis A., Roila F., Feyer P.: (2017) 2016 updated MASCC/ESMO consensus recommendations: prevention of radiotherapy-induced nausea and vomiting. SUPPORTIVE CARE IN CANCER, 25: 309-316 27624464

Schaffrath J., Schmoll H.J., Voigt W., Müller L.P., Müller-Tidow C., Mueller T.: (2017) Efficacy of targeted drugs in germ cell cancer cell lines with differential cisplatin sensitivity. PLoS One, 12: e0178930 28591197

Schmidt H., Boese S., Lampe K., Jordan K., Fiedler E., Müller-Werdan U., Wienke A., Vordermark D.: (2017) Trans sectoral care of geriatric cancer patients based on comprehensive geriatric assessment and patient-reported quality of life - Results of a multicenter study to develop and pilot test a patient-centered interdisciplinary care concept for geriatric oncology patients (PIVOG). Journal of Geriatric Oncology, 8: 262-270 28533106

Seymour J.F., Döhner H., Butrym A., Wierzbowska A., Selleslag D., Jang J.H., Kumar R., Cavenagh J., Schuh A.C., Candoni A., Récher C., Sandhu I., Del Castillo T.B., Al-Ali H.K., Falantes J., Stone R.M., Minden M.D., Weaver J., Songer S., Beach C.L., Dombret H.: (2017) Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens. BMC CANCER, 17: 852 29241450

Simmermacher S., Vordermark D., Kegel T., Strauss C.: (2017) Malignization of a vestibular schwannoma 13 years after radiation therapy. HNO, 65: 153-157 28567476

Thoennissen G.B., Görlich D., Bacher U., Aufenberg T., Hüsken A.C., Hansmeier A.A., Evers G., Mikesch J.H., Fritz F., Bokemeyer C., Müller-Tidow C., Stelljes M., Mesters R.M., Krug U., Kropff M.H., Thoennissen N.H., Berdel W.E.: (2017) Autologous Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Drug Induction: A Retrospective Single-Center Analysis. ACTA HAEMATOLOGICA, 137: 163-172 28399522

Zhou F., Liu Y., Rohde C., Pauli C., Gerloff D., Köhn M., Misiak D., Bäumer N., Cui C., Göllner S., Oellerich T., Serve H., Garcia-Cuellar M.P., Slany R., Maciejewski J.P., Przychodzen B., Seliger B., Klein H.U., Bartenhagen C., Berdel W.E., Dugas M., Taketo M.M., Farouq D., Schwartz S., Regev A., Hébert J., Sauvageau G., Pabst C., Hüttelmaier S., Müller-Tidow C.: (2017) AML1-ETO requires enhanced C/D box snoRNA/RNP formation to induce self-renewal and leukaemia. NATURE CELL BIOLOGY, 19: 844-855 28650479

Aapro M., Hesketh P.J., Jordan K., Gralla R.J., Rossi G., Rizzi G., Palmas M.: (2016) Safety of an Oral Fixed Combination of Netupitant and Palonosetron (NEPA): Pooled Data From the Phase II/III Clinical Program.
ONCOLOGIST, 21: 494-502 27000465

Alsdorf W.H., Schmitz M., Schieferdecker A., Dierlamm J., Bokemeyer C., Binder M.: (2016) Severe and irreversible myelopathy after concurrent systemic and intrathecal nucleoside analogue treatment for refractory diffuse large B-cell lymphoma: A case report and review of the literature. JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 22: 523-7 25655468

Bäumer N., Appel N., Terheyden L., Buchholz F., Rossig C., Müller-Tidow C., Berdel W.E., Bäumer S.: (2016) Antibody-coupled siRNA as an efficient method for in vivo mRNA knockdown. Nature Protocols, 11: 22-36 26633129

Benkisser-Petersen M., Buchner M., Dörffel A., Dühren-von-Minden M., Claus R., Kläsener K., Leberecht K., Burger M., Dierks C., Jumaa H., Malavasi F., Reth M., Veelken H., Duyster J., Zirlik K.: (2016) Spleen Tyrosine Kinase Is Involved in the CD38 Signal Transduction Pathway in Chronic Lymphocytic Leukemia. PLoS One, 11: e0169159 28036404

Braig F., Voigtlaender M., Schieferdecker A., Busch C.J., Laban S., Grob T., Kriegs M., Knecht R., Bokemeyer C., Binder M.: (2016) Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma. ONCOTARGET, 7: 42988-42995 27119512

Bzymek R., Horsthemke M., Isfort K., Mohr S., Tjaden K., Müller-Tidow C., Thomann M., Schwerdtle T., Bähler M., Schwab A., Hanley P.J.: (2016) Real-time two- and three-dimensional imaging of monocyte motility and navigation on planar surfaces and in collagen matrices: roles of Rho. Scientific Reports, 6: 25016 27122054

Chaturvedi A., Araujo Cruz M.M., Jyotsana N., Sharma A., Goparaju R., Schwarzer A., Görlich K., Schottmann R., Struys E.A., Jansen E.E., Rohde C., Müller-Tidow C., Geffers R., Göhring G., Ganser A., Thol F., Heuser M.: (2016) Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarate. LEUKEMIA, 30: 1708-15 27063596

Etrych T., Lucas H., Janoušková O., Chytil P., Mueller T., Mäder K.: (2016) Fluorescence optical imaging in anticancer drug delivery. JOURNAL OF CONTROLLED RELEASE, 226: 168-81 26892751

Ferreri A.J.M., Cwynarski K., Pulczynski E., Ponzoni M., Deckert M., Politi L.S., Torri V., Fox C.P., Rosée P.L., Schorb E., Ambrosetti A., Roth A., Hemmaway C., Ferrari A., Linton K.M., Rudà R., Binder M., Pukrop T., Balzarotti M., Fabbri A., Johnson P., Gørløv J.S., Hess G., Panse J., Pisani F., Tucci A., Stilgenbauer S., Hertenstein B., Keller U., Krause S.W., Levis A., Schmoll H.J., Cavalli F., Finke J., Reni M., Zucca E., Illerhaus G., International Extranodal Lymphoma Study Group (IELSG): (2016) Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematology, 3:
e217-27 27132696

Fichtner M., Spies E., Seismann H., Riecken K., Engels N., Gösch B., Dierlamm J., Gerull H., Nollau P., Klapper W., Dreyling M., Binder M., Trepel M.: (2016) Complementarity determining region-independent recognition of a superantigen by B-cell antigen receptors of mantle cell lymphoma. HAEMATOLOGICA, 101: e378-81 27582571

Grabner A., Kentrup D., Pawelski H., Mühlmeister M., Biermann C., Edemir B., Heitplatz B., Van Marck V., Bettinger T., Pavenstädt H., Schlatter E., Stypmann J., Tiemann K., Reuter S.: (2016) Renal Contrast-Enhanced Sonography Findings in a Model of Acute Cellular Allograft Rejection. AMERICAN JOURNAL OF TRANSPLANTATION, 16: 1612-9 26613381

Harrach S., Schmidt-Lauber C., Pap T., Pavenstädt H., Schlatter E., Schmidt E., Berdel W.E., Schulze U., Edemir B., Jeromin S., Haferlach T., Ciarimboli G., Bertrand J.: (2016) MATE1 regulates cellular uptake and sensitivity to imatinib in CML patients. Blood Cancer Journal, 6: e470 27635733

Heinrich A.K., Lucas H., Schindler L., Chytil P., Etrych T., Mäder K., Mueller T.: (2016) Improved Tumor-Specific Drug Accumulation by Polymer Therapeutics with pH-Sensitive Drug Release Overcomes Chemotherapy Resistance. MOLECULAR CANCER THERAPEUTICS, 15: 998-1007 26939698

Herrtwich L., Nanda I., Evangelou K., Nikolova T., Horn V., Sagar, Erny D., Stefanowski J., Rogell L., Klein C., Gharun K., Follo M., Seidl M., Kremer B., Münke N., Senges J., Fliegauf M., Aschman T., Pfeifer D., Sarrazin S., Sieweke M.H., Wagner D., Dierks C., Haaf T., Ness T., Zaiss M.M., Voll R.E., Deshmukh S.D., Prinz M., Goldmann T., Hölscher C., Hauser A.E., Lopez-Contreras A.J., Grün D., Gorgoulis V., Diefenbach A., Henneke P., Triantafyllopoulou A.: (2016) DNA Damage Signaling Instructs Polyploid Macrophage Fate in Granulomas. CELL, 167: 1264-1280.e18 28084216

Hesketh P.J., Bohlke K., Lyman G.H., Basch E., Chesney M., Clark-Snow R.A., Danso M.A., Jordan K., Somerfield M.R., Kris M.G., American Society of Clinical Oncology: (2016) Antiemetics: American Society of Clinical Oncology Focused Guideline Update. JOURNAL OF CLINICAL ONCOLOGY, 34: 381-6 26527784

Hesketh P.J., Schnadig I.D., Schwartzberg L.S., Modiano M.R., Jordan K., Arora S., Powers D., Aapro M.: (2016) Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy. CANCER, 122: 2418-25 27176138

Illerhaus G., Kasenda B., Ihorst G., Egerer G., Lamprecht M., Keller U., Wolf H.H., Hirt C., Stilgenbauer S., Binder M., Hau P., Edinger M., Frickhofen N., Bentz M., Möhle R., Röth A., Pfreundschuh M., von Baumgarten L., Deckert M., Hader C., Fricker H., Valk E., Schorb E., Fritsch K., Finke J.: (2016) High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial. Lancet Haematology, 3: e388-97 27476790

Jakobs A., Uttarkar S., Schomburg C., Steinmann S., Coulibaly A., Schlenke P., Berdel W.E., Müller-Tidow C., Schmidt T.J., Klempnauer K.H.: (2016) An isoform-specific C/EBPβ inhibitor targets acute myeloid leukemia cells. LEUKEMIA, 30: 1612-5 26854027

Jordan B., Jahn F., Beckmann J., Unverzagt S., Müller-Tidow C., Jordan K.: (2016) Calcium and Magnesium Infusions for the Prevention of Oxaliplatin-Induced Peripheral Neurotoxicity: A Systematic Review. ONCOLOGY, 90: 299-306 27169552

Jordan B., Kellner J., Jordan K., Bähre M., Behrmann C., Zierz S.: (2016) Thymic pathologies in myasthenia gravis: a preoperative assessment of CAT scan and nuclear based imaging. JOURNAL OF NEUROLOGY, 263: 641-8 26810725

Jordan K., Gralla R., Rizzi G., Kashef K.: (2016) Efficacy benefit of an NK1 receptor antagonist (NK1RA) in patients receiving carboplatin: supportive evidence with NEPA (a fixed combination of the NK1 RA, netupitant, and palonosetron) and aprepitant regimens. SUPPORTIVE CARE IN CANCER, 24: 4617-25 27334131

Jordan K., Warr D.G., Hinke A., Sun L., Hesketh P.J.: (2016) Defining the efficacy of neurokinin-1 receptor antagonists in controlling chemotherapy-induced nausea and vomiting in different emetogenic settings-a metaanalysis. SUPPORTIVE CARE IN CANCER, 24: 1941-54 26476625

Jordan K., Luetkens T., Gog C., Killing B., Arnold D., Hinke A., Stahl M., Freier W., Rüssel J., Atanackovic D., Hegewisch-Becker S.: (2016) Intraperitoneal bevacizumab for control of malignant ascites due to advanced-stage gastrointestinal cancers: A multicentre double-blind, placebo-controlled phase II study - AIO SUP-0108. EUROPEAN JOURNAL OF CANCER, 63: 127-34 27314448

Klein C., Zwick A., Kissel S., Forster C.U., Pfeifer D., Follo M., Illert A.L., Decker S., Benkler T., Pahl H., Oostendorp R.A.J., Aumann K., Duyster J., Dierks C.: (2016) Ptch2 loss drives myeloproliferation and myeloproliferative neoplasm progression. JOURNAL OF EXPERIMENTAL MEDICINE, 213: 273-90 26834157

Kriegs M., Kasten-Pisula U., Riepen B., Hoffer K., Struve N., Myllynen L., Braig F., Binder M., Rieckmann T., Grénman R., Petersen C., Dikomey E., Rothkamm K.: (2016) Radiosensitization of HNSCC cells by EGFR inhibition depends on the induction of cell cycle arrests. ONCOTARGET, 7: 45122-45133 27281611

Liebscher G., Vanchangiri K., Mueller T., Feige K., Cavalleri J.M.V., Paschke R.: (2016) In vitro anticancer activity of Betulinic acid and derivatives thereof on equine melanoma cell lines from grey horses and in vivo safety assessment of the compound NVX-207 in two horses. CHEMICO-BIOLOGICAL INTERACTIONS, 246: 20-9 26772157

Lomkova E.A., Chytil P., Janoušková O., Mueller T., Lucas H., Filippov S.K., Trhlíková O., Aleshunin P.A., Skorik Y.A., Ulbrich K., Etrych T.: (2016) Biodegradable Micellar HPMA-Based Polymer-Drug Conjugates with Betulinic Acid for Passive Tumor Targeting. BIOMACROMOLECULES, 17: 3493-3507 27636143

Mahal K., Biersack B., Schruefer S., Resch M., Ficner R., Schobert R., Mueller T.: (2016) Combretastatin A-4 derived 5-(1-methyl-4-phenyl-imidazol-5-yl)indoles with superior cytotoxic and anti-vascular effects on chemoresistant cancer cells and tumors. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 118: 9-20 27116710

Maurer C., Pflug N., Bahlo J., Kluth S., Rhein C., Cramer P., Gross-Ophoff C., Langerbeins P., Fink A.M., Eichhorst B., Kreuzer K.A., Fischer N., Tausch E., Stilgenbauer S., Böttcher S., Döhner H., Kneba M., Dreyling M., Binder M., Hallek M., Wendtner C.M., Bergmann M., Fischer K., German CLL Study Group: (2016) Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia. EUROPEAN JOURNAL OF HAEMATOLOGY, 97: 253-60 26643449

Moehler M., Gepfner-Tuma I., Maderer A., Thuss-Patience P.C., Ruessel J., Hegewisch-Becker S., Wilke H., Al-Batran S.E., Rafiyan M.R., Weißinger F., Schmoll H.J., Kullmann F., von Weikersthal L.F., Siveke J.T., Weusmann J., Kanzler S., Schimanski C.C., Otte M., Schollenberger L., Koenig J., Galle P.R.: (2016) Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program. BMC CANCER, 16: 699 27582078

Müller-Tidow C., Tschanter P., Röllig C., Thiede C., Koschmieder A., Stelljes M., Koschmieder S., Dugas M., Gerss J., Butterfaß-Bahloul T., Wagner R., Eveslage M., Thiem U., Krause S.W., Kaiser U., Kunzmann V., Steffen B., Noppeney R., Herr W., Baldus C.D., Schmitz N., Götze K., Reichle A., Kaufmann M., Neubauer A., Schäfer-Eckart K., Hänel M., Peceny R., Frickhofen N., Kiehl M., Giagounidis A., Görner M., Repp R., Link H., Kiani A., Naumann R., Brümmendorf T.H., Serve H., Ehninger G., Berdel W.E., Krug U., Study Alliance Leukemia Group: (2016) Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the Study Alliance Leukemia. LEUKEMIA, 30: 555-61 26522083

Pabst C., Bergeron A., Lavallée V.P., Yeh J., Gendron P., Norddahl G.L., Krosl J., Boivin I., Deneault E., Simard J., Imren S., Boucher G., Eppert K., Herold T., Bohlander S.K., Humphries K., Lemieux S., Hébert J., Sauvageau G., Barabé F.: (2016) GPR56 identifies primary human acute myeloid leukemia cells with high repopulating potential in vivo. BLOOD, 127: 2018-27 26834243

Pohlen M., Groth C., Sauer T., Görlich D., Mesters R., Schliemann C., Lenz G., Müller-Tidow C., Büchner T., Berdel W.E., Stelljes M.: (2016) Outcome of allogeneic stem cell transplantation for AML and myelodysplastic syndrome in elderly patients (⩾60 years). BONE MARROW TRANSPLANTATION, 51: 1441-1448 27295269

Pohlen M., Marx J., Mellmann A., Becker K., Mesters R.M., Mikesch J.H., Schliemann C., Lenz G., Müller-Tidow C., Büchner T., Krug U., Stelljes M., Karch H., Peters G., Gerth H.U., Görlich D., Berdel W.E.: (2016) Ciprofloxacin versus colistin prophylaxis during neutropenia in acute myeloid leukemia: two parallel patient cohorts treated in a single center. HAEMATOLOGICA, 101: 1208-1215 27470601

Pola R., Heinrich A.K., Mueller T., Kostka L., Mäder K., Pechar M., Etrych T.: (2016) Passive Tumor Targeting of Polymer Therapeutics: In Vivo Imaging of Both the Polymer Carrier and the Enzymatically Cleavable Drug Model. MACROMOLECULAR BIOSCIENCE, 16: 1577-1582 27654467

Potratz J., Tillmanns A., Berning P., Korsching E., Schaefer C., Lechtape B., Schleithoff C., Unland R., Schäfer K.L., Müller-Tidow C., Jürgens H., Dirksen U.: (2016) Receptor tyrosine kinase gene expression profiles of Ewing sarcomas reveal ROR1 as a potential therapeutic target in metastatic disease. Molecular Oncology, 10: 677-92 26739507 

Riemke P., Czeh M., Fischer J., Walter C., Ghani S., Zepper M., Agelopoulos K., Lettermann S., Gebhardt M.L., Mah N., Weilemann A., Grau M., Gröning V., Haferlach T., Lenze D., Delwel R., Prinz M., Andrade-Navarro M.A., Lenz G., Dugas M., Müller-Tidow C., Rosenbauer F.: (2016) Myeloid leukemia with transdifferentiation plasticity developing from T-cell progenitors. EMBO JOURNAL, 35: 2399-2416 27572462

Roila F., Molassiotis A., Herrstedt J., Aapro M., Gralla R.J., Bruera E., Clark-Snow R.A., Dupuis L.L., Einhorn L.H., Feyer P., Hesketh P.J., Jordan K., Olver I., Rapoport B.L., Roscoe J., Ruhlmann C.H., Walsh D., Warr D., van der Wetering M., participants of the MASCC/ESMO Consensus Conference Copenhagen 2015: (2016) 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. ANNALS OF ONCOLOGY, 27: v119-v133 27664248

Schelhaas S., Held A., Bäumer N., Viel T., Hermann S., Müller-Tidow C., Jacobs A.H.: (2016) Preclinical Evidence That 3'-Deoxy-3'-[18F]Fluorothymidine PET Can Visualize Recovery of Hematopoiesis after Gemcitabine Chemotherapy. CANCER RESEARCH, 76: 7089-7095 27923827

Schemionek M., Herrmann O., Reher M.M., Chatain N., Schubert C., Costa I.G., Hänzelmann S., Gusmao E.G., Kintsler S., Braunschweig T., Hamilton A., Helgason G.V., Copland M., Schwab A., Müller-Tidow C., Li S., Holyoake T.L., Brümmendorf T.H., Koschmieder S.: (2016) Mtss1 is a critical epigenetically regulated tumor suppressor in
CML. LEUKEMIA, 30: 823-32 26621336

Schieferdecker A., Oberle A., Thiele B., Hofmann F., Göthel M., Miethe S., Hust M., Braig F., Voigt M., von Pein U.M., Koch-Nolte F., Haag F., Alawi M., Indenbirken D., Grundhoff A., Bokemeyer C., Bacher U., Kröger N., Binder M.: (2016) A transplant "immunome" screening platform defines a targetable epitope fingerprint of multiple myeloma. BLOOD, 127: 3202-14 27034429

Schliffke S., Akyüz N., Ford C.T., Mährle T., Thenhausen T., Krohn-Grimberghe A., Knop S., Bokemeyer C., Binder M.: (2016) Clinical response to ibrutinib is accompanied by normalization of the T-cell environment in CLL-related autoimmune cytopenia. LEUKEMIA, 30: 2232-2234 27220665

Schmidt H., Merkel D., Koehler M., Flechtner H.H., Sigle J., Klinge B., Jordan K., Vordermark D., Landenberger M., Jahn P.: (2016) PRO-ONKO-selection of patient-reported outcome assessments for the clinical use in cancer patients-a mixed-method multicenter cross-sectional exploratory study. SUPPORTIVE CARE IN CANCER, 24: 2503-12 26676238

Schmitt F., Donnelly K., Muenzner J.K., Rehm T., Novohradsky V., Brabec V., Kasparkova J., Albrecht M., Schobert R., Mueller T.: (2016) Effects of histidin-2-ylidene vs. imidazol-2-ylidene ligands on the anticancer and antivascular activity of complexes of ruthenium, iridium, platinum, and gold. JOURNAL OF INORGANIC BIOCHEMISTRY, 163: 221-228 27491634

Schulze Blasum B., Schröter R., Neugebauer U., Hofschröer V., Pavenstädt H., Ciarimboli G., Schlatter E., Edemir B.: (2016) The kidney-specific expression of genes can be modulated by the extracellular osmolality. FASEB JOURNAL, 30: 3588-3597

Schulze I., Rohde C., Scheller-Wendorff M., Bäumer N., Krause A., Herbst F., Riemke P., Hebestreit K., Tschanter P., Lin Q., Linhart H., Godley L.A., Glimm H., Dugas M., Wagner W., Berdel W.E., Rosenbauer F., Müller-Tidow C.: (2016) Increased DNA methylation of Dnmt3b targets impairs leukemogenesis. BLOOD, 127: 1575-86 26729896

Shumilov E., Wulf G., Ströbel P., Hasenkamp J., Hellige N., Bleckmann A., Haase D., Braulke F., Jung W., Schanz J., Binder M., Trümper L., Bacher U.: (2016) Osteolytic lesions occur rarely in patients with B-CLL and may respond well to ibrutinib. LEUKEMIA & LYMPHOMA, 57: 2476-80 26916814

Stucke-Ring J., Ronnacker J., Brand C., Höltke C., Schliemann C., Kessler T., Schmidt L.H., Harrach S., Mantke V., Hintelmann H., Hartmann W., Wardelmann E., Lenz G., Wünsch B., Müller-Tidow C., Mesters R.M., Schwöppe C., Berdel W.E.: (2016) Combinatorial effects of doxorubicin and retargeted tissue factor by intratumoral entrapment of doxorubicin and proapoptotic increase of tumor vascular infarction. ONCOTARGET, 7: 82458-82472 27738341

Sun H., Lin D.C., Guo X., Kharabi Masouleh B., Gery S., Cao Q., Alkan S., Ikezoe T., Akiba C., Paquette R., Chien W., Müller-Tidow C., Jing Y., Agelopoulos K., Müschen M., Koeffler H.P.: (2016) Inhibition of IRE1α-driven prosurvival pathways is a promising therapeutic application in acute myeloid leukemia. ONCOTARGET, 7: 18736-49 26934650

Uttarkar S., Dassé E., Coulibaly A., Steinmann S., Jakobs A., Schomburg C., Trentmann A., Jose J., Schlenke P., Berdel W.E., Schmidt T.J., Müller-Tidow C., Frampton J., Klempnauer K.H.: (2016) Targeting acute myeloid leukemia with a small molecule inhibitor of the Myb/p300 interaction. BLOOD, 127: 1173-82 26631113

Uttarkar S., Piontek T., Dukare S., Schomburg C., Schlenke P., Berdel W.E., Müller-Tidow C., Schmidt T.J., Klempnauer K.H.: (2016) Small-Molecule Disruption of the Myb/p300 Cooperation Targets Acute Myeloid Leukemia Cells. MOLECULAR CANCER THERAPEUTICS, 15: 2905-2915 27707899

Vitavska O., Edemir B., Wieczorek H.: (2016) Putative role of the H(+)/sucrose symporter SLC45A3 as an osmolyte transporter in the kidney. PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY, 468: 1353-62 27228996

von Lilienfeld-Toal M., Berger A., Christopeit M., Hentrich M., Heussel C.P., Kalkreuth J., Klein M., Kochanek M., Penack O., Hauf E., Rieger C., Silling G., Vehreschild M., Weber T., Wolf H.H., Lehners N., Schalk E., Mayer K.: (2016) Community acquired respiratory virus infections in cancer patients-Guideline on diagnosis and management by the Infectious Diseases Working Party of the German Society for haematology and Medical Oncology. EUROPEAN JOURNAL OF CANCER, 67: 200-212 27681877

Wass M., Hitz F., Schaffrath J., Müller-Tidow C., Müller L.P.: (2016) Value of Different Comorbidity Indices for Predicting Outcome in Patients with Acute Myeloid Leukemia. PLoS One, 11: e0164587 27732646

Weber T., Niestadtkötter J., Wienke A., Müller-Tidow C., Müller L.P.: (2016) Enteric-coated mycophenolate sodium
containing GvHD prophylaxis reduces GvHD rate after allogeneic HSCT. EUROPEAN JOURNAL OF HAEMATOLOGY, 97: 232-8 26613546

Weinstein C., Jordan K., Green S.A., Camacho E., Khanani S., Beckford-Brathwaite E., Vallejos W., Liang L.W., Noga S.J., Rapoport B.L.: (2016) Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial. ANNALS OF ONCOLOGY, 27: 172-8 26449391

Widder M., Lützkendorf J., Caysa H., Unverzagt S., Wickenhauser C., Benndorf R.A., Schmoll H.J., Müller-Tidow C., Müller T., Müller L.P.: (2016) Multipotent mesenchymal stromal cells promote tumor growth in distinct colorectal cancer cells by a β1-integrin-dependent mechanism. INTERNATIONAL JOURNAL OF CANCER, 138: 964-75  26356035

Wolf H.H., Kornhuber M.E., Weis J., Posa A.: (2016) Dysautonomic polyneuropathy as a variant of chronic inflammatory "demyelinating" polyneuropathy? CLINICAL AUTONOMIC RESEARCH, 26: 303-5 27379500